WO2011025906A1 - Long term potentiation with cyclic-glur6 analogs - Google Patents

Long term potentiation with cyclic-glur6 analogs Download PDF

Info

Publication number
WO2011025906A1
WO2011025906A1 PCT/US2010/046891 US2010046891W WO2011025906A1 WO 2011025906 A1 WO2011025906 A1 WO 2011025906A1 US 2010046891 W US2010046891 W US 2010046891W WO 2011025906 A1 WO2011025906 A1 WO 2011025906A1
Authority
WO
WIPO (PCT)
Prior art keywords
ltp
nmda
term potentiation
marshall
synaptic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/046891
Other languages
French (fr)
Inventor
John Marshall
Andrew Mallon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University
Original Assignee
Brown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University filed Critical Brown University
Priority to US13/389,047 priority Critical patent/US8673857B2/en
Publication of WO2011025906A1 publication Critical patent/WO2011025906A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • This invention employs a composition (shown below) that facilitates the induction of long-term potentiation (LTP). Without being bound by any particular theory, it is believed that LTP is the cellular manifestation of learning and memory.
  • composition (one analog of which is termed CN2097) is a reversible modulator of at least one neuron-specific PDZ domain comprising
  • R is a molecular transporter with or without a linker amino acid
  • Ri is at least about one amino acid covalently bound
  • R 2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use. Disruptions in LTP lead to disruptions in memory and has been associated with several neurological disorders, including autism syndromes and neurodegenerative disorders.
  • CN 2097 is a peptidomimetic drug that selectively targets the PDZ binding domain of the PSD-95, a scaffolding protein involved in the development and regulation of neuronal synapses CN 2097 has demonstrated specificity for the NMDA receptor 2B (NR2B) subunit.
  • NR2B NMDA receptor 2B
  • the association of PSD-95 with NMDA receptors is an element in the propagation of the synaptic changes of LTP and long-term depression (LTD) that induce learning and memory.
  • PSD-95 is a member of the MAGUK-family of PDZ domain-containing proteins. Its basic structure includes three PDZ domains, an SH3 domain, and a guanylate kinase-like domain (GK).
  • Angelman syndrome is a result of loss-of-function mutations or deletions in the maternally inherited allele of UBE3A. Mice that are deficient in maternal Ube3a also show genetically reversible deficits in learning and the induction of hippocampal long-term potentiation (LTP) 1 " 3 , a form of synaptic plasticity. Angelman syndrome (AS) is caused by disruptions in function due to mutations and/or deletions in the maternally inherited allele of an E3 ubiquitin ligase, UBE3A, a gene that has also been implicated in the broader spectrum of Autism patients.
  • LTP hippocampal long-term potentiation
  • a mouse model for AS carries the maternally inherited Ube3a-null mutation and shows profound impairments in hippocampal synaptic plasticity as seen in Fig. 8. It has been reported that UBE3 A is also required for experience dependent maturation in the visual cortex. In particular, AS mice show deficits in long-term potentiation (LTP) and long-term depression (LTD), which are the cellular substrates of learning and memory. These forms of synaptic plasticity are highly regulated by activity-dependent changes in the ratio of NMDA subunits, specifically NR2A and NR2B subunits. NMDA receptors gate the influx of calcium ions across the post-synaptic membrane.
  • SS Szeto-Schiller peptide
  • the structural motif of the SS peptide centers on alternating aromatic residues and basic amino acids (aromatic-cationic peptides). They are small, easy to synthesize, readily soluble in water, and resistant to peptidase degradation. The presence of a D- amino acid in either the first or second position renders them resistant to aminopeptidase activity, and amidation of the C-terminus reduces hydrolysis from the C-terminus. Despite carrying 3+ net charge at physiological pH, these peptides have been reported to readily penetrate cell membranes of a variety of cell types. This is further set forth
  • Neurotrophins are a family of neurotrophic factors involved in the development, maintenance, and repair of the nervous system.
  • the neurotrophin family consists of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin- 3 (NT-3) and NT-4/5.
  • the neurotrophins are believed to bind to and activate Trk family proteins, the receptor tyrosine kinases (RTK), to exert their effects.
  • NGF binds to TrkA, BDNF and NT- 4/5 bind to TrkB, and NT-3 binds to TrkC.
  • the neurotrophins BDNF and NGF and their high- affinity receptor Trk receptor are reported as widely expressed in neurons throughout the central nervous system. Binding of neurotrophins to Trk receptor is reported to result in
  • N-methyl-d-aspartate receptor subunit composition in the rat visual cortex during postnatal development. Proceedings of the National Academy of Sciences of the
  • IGF-I- modulation of CaVl.3 calcium channels depends on Ca +2 release from ⁇ Vsenstitive stores and CaMKII -phosphorylation of the alpha 1 subunit EF hand. J.Neurosci. 26, 6259-68.
  • SAP90 binds and clusters kainate receptors causing incomplete desensitization. Neuron 21, 727-39.
  • Green Fluorescent Protein A new tool for studying ion channel expression. Neuron 14, 211-215.
  • Fig. 1 is a representation of CN2907.
  • Fig. 2 shows a sub-threshold LTP induction protocol at the adult Wistar rat Schaffer Collateral-
  • Fig. 3 presents a single, whole cell patch recording of a pharmacologically isolated NMDA excitatory postsynaptic current (EPSC) of a pyramidal neuron in the CAl region of the hippocampus and the lack of effect upon this current by perfusion of CN2097 2 ⁇ M.
  • APV is a selective NMDA receptor antagonist.
  • Fig. 4 presents data from a ⁇ 2 month WT mouse hippocampal slice
  • HFS High Frequency Stimuli
  • Fig. 5 presents data from a WT mouse hippocampal slice.
  • An arrow indicates the time point at which one, sub-threshold, High Frequency Stimuli (HFS, 100 pulse in 1 second every 10ms, i.e.
  • HFS High Frequency Stimuli
  • Fig. 6 presents data from a WT mouse adult hippocampal slice.
  • An arrow indicates the time point at which one sub-threshold High Frequency Stimuli (HFS, 100 pulse in 1 second every 10ms, 100Hz) was applied.
  • CN5135 is a less active analogue of CN2097, with alanine mutations in the 0 and -2 ring positions that contain the posited critical PDZ binding moiety.
  • HFS High Frequency Stimuli
  • Fig. 9 displays data from AS mouse (Ube3am-/p+) hippocampal slices which were recorded for 0-20 minutes observing a stable baseline. Then CN2097 2 ⁇ M was superfused from 20-
  • the arrow at 40minutes indicates three trains of High Frequency Stimuli 10 seconds apart .
  • the HFS is 100 pulses in 1 second with an interpulse interval of 10ms, i.e. 100Hz.. This results in a significant increase in the synaptic strength (LTP).
  • LTP synaptic strength
  • AS mice this stimulation is normally unable to induce LTP (Fig 8.).
  • This invention includes inducing long-term potentiation in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound.
  • the method employs dosage is from about lmg/Kg to about 10 mg/Kg, and particularly from about 4mg/Kg to about 6 mg/Kg, with particular reference to about 5 mg/Kg.
  • the method of the invention employs dosages which establish a blood and CNS level of about 0.1 to about 10 ⁇ M, with particular reference to about 2 ⁇ M to about 4 ⁇ M.
  • CN 2097 may induce its therapeutic effects by the modulation of other PDZ domains, including, but not limited to, Shank, S-SCAM, Pick, GRIP and MAGI.
  • this invention discloses a method of treating conditions selected from the group consisting of Angelman Syndrome, Alzheimer's Disease, cognitive disorders, learning disorders, or autism spectrum disorders by facilitating the induction of Long- Term Potentiation and Long-term Depression in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound.
  • heterozygous mice lacking the Ube3a gene maternally we crossed a heterozygous female mouse (m-/p+) with a wild-type male mouse (m+/p+). Wild type (WT) littermates (m+/p+) were used as controls.
  • Cyclic-GluR6 Analogs (CN2907-like compounds) shall mean a composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising
  • R is a molecular transporter with or without a linker amino acid
  • Ri is at least about one amino acid covalently bound; and, R 2 is isoleucine, leucine, alanine, phenylalanine, or valine.
  • LTP Long-Term Potentiation
  • LTP neuronal cells that would normally not be induced, which is a 2-step regimen of drug and pulses.
  • post-dosing LTP is induced with three, one second, 100Hz pulses of current 10 seconds apart.
  • the therapeutic regimen alters (lowers) the experience dependent threshold for the consolidation and acquisition of memory and thus learning.
  • this drug enhances the encoding of information and skills into long term memory.
  • CN 2097 is a peptidomimetic drug that selectively targets the PDZ binding domain of the PSD-95, a scaffolding protein involved in the development and regulation of neuronal synapses. It is further contemplated as treating neurological conditions characterized by deficits in cognition (primary or co-morbidity) such as schizophrenia, Alzeheimer's disease, Fragile -X syndrome, autism and "life style" drug damage (e.g., methamphetamine, PCP, cocaine etc).
  • the NMDA receptor 2B (NR2B) subunit is involved in learning and memory, including its cellular correlatives, LTP and LTD.
  • szeto(SS) peptide analogue of CN 2097 having szeto instead of the poly-Arg tail
  • CN5135 having szeto instead of the poly-Arg tail
  • TAT tat-NR2B9c
  • extrasynaptic receptor populations include GABA A including subunits ⁇ 5 ⁇ and/or ⁇ 4 ⁇ , glutamate NR2B and NR2A subunit containing NMDA receptors.
  • the peptide KNYKKTEV which codes for the CRIPT PDZ-3 binding motif, was cyclized between the valine (V) and threonine (T) residues via beta-alanine linkage and either myristylated (CN2180) or linked to a poly-arginine tail (CN2097; Fig. 1) to enhance its diffusion and uptake capacity by neurons in intact tissues.
  • CN2180 Binding specificity of CN2180 was tested against a PDZ-domain array consisting of 96 distinct His-tagged PDZ domains purified and spotted on a gridded nylon membrane. CN2180 showed high specificity to the PDZ1-PDZ2 domains and moderate binding to the PDZ3 domain of PSD- 95, but did not bind to PDZ domains of other MAGUKS or with other PDZ-containing proteins such as MUPPl, S-SCAM, Shank and spinophilin. In electrophysiological and biochemical preliminary studies CN 2097 demonstrates specificity toward the NR2B NMDAR subunit.
  • CN 2097 acts as competitive ligand for this binding site and as such is able to disrupt the normal binding of NR2B receptors to the PSD. Also, it is believed that CN2097 disrupts NR2B downstream signaling by displacing signaling effectors attached directly or indirectly to the NR2B/PSD-95 signaling complex including CaMKII. Excitotoxic studies suggest that CN 2097 is neuroprotective in both the retina and the hippocampus against lethal doses of NMDA.
  • this effect is believed due to the disruption of apoptotic and necrotic cell signaling pathways that propagate the cell death signal.
  • Neutrophin signaling proteins are believed to link Trk activation to Ras and the downstream activation of mitogen-activated protein kinases (MAPKs) and the
  • PI3K phosphatidylinositol 3-kinase
  • PI3K phosphatidylinositol 3-kinase
  • Inhibition of p-JNK in particular is a pro-survival effect.
  • JNK is a cell death signaling protein.
  • upregulation of CaMKII, an NMDAR-PSD-95 associated protein is believed to be associated with synaptic plasticity. Biochemical analyses using western blots of in vivo injected retinas, cultured SH-SY5Y neuroblastomas and primary cultured mouse cerebellar granule neurons (CGN) was undertaken.
  • CGNs were stimulated by a paradigm designed to mimic synaptic stimulation (lO ⁇ M glycine, 40 ⁇ M bicuculline and 4 ⁇ M picrotoxin in ACSF) and SH-SY5Y cells were activated by nerve growth factor (NGF 50ng/ml).
  • CN2097 yielded a variety effects on the mTOR, S6 and AKT expression pathways including increases in both total protein expression and phosphorylation state (CamKII, ERK, AKT 1/2, p-S6K, p-S6, p- ERK, p-p38) and inhibiting p-JNK. Additionally CN2097 increased the expression CREB, which is also neuroprotective. Also observed were increases in levels of PSD-95. This data are evidence that CN2097 is proviing a neuroprotective effect at the level of the cell death 'master switch'.
  • tat-NR2B9c (TAT, 2 ⁇ M)
  • TAT tat-NR2B9c
  • SH-SY5Y neuroblastoma cell culture line
  • NGF nerve growth factor
  • CN2097 saw increased ERK, AKT 1/2, p-S6K, p-S6, p-ERK, p-p38, p-CREB and PSD-95. Additionally, CN2097 (2 ⁇ M) inhibited p-JNK.
  • CN2097S (szeto sequence used instead of PoI- Arginine) and CN5135 (2, 10 and 20 ⁇ M), a structural analogue of CN2097 with disruptive alanine substitutions at the 0 and -2 ring positions (binding domain) were used a negative controls whilst tat-NR2B9c (TAT, 2 ⁇ M) was used as a positive control.
  • ACPD an agonist of mGluRl , when CN2097 is added leads to an enhancement of PI3K and AKT signaling.
  • CN 2097 is effective in synaptic plasticity and is able to lower the threshold for LTP induction, as shown Fig. 2.
  • Fig. 2 shows Sub-threshold LTP induction at the Schaffer Collateral- CAl synapse is rescued by CN 2097.
  • using a low intensity 1 second 100Hz (HFS) stimulation train that normally fails to induce LTP was added 2 ⁇ M CN 2097 which induced a significant LTP (black circles) that lasted for over 60minutes.
  • HTS low intensity 1 second 100Hz
  • CN 2097 acts through its ability to specifically interfere with NR2B activity and expression to change the sliding threshold for synaptic plasticity, altering the ratio of NR2A:NR2B.
  • NR2B has been reported to lower the threshold for synaptic plasticity, such that LTP can be induced in response to a normally impotent stimulation with NMDA agonist.
  • CN 2097 is believed to mimic this effect without displaying the toxicity and side effects associated with simple receptor antagonists that block basal transmission, since it does not act as an antagonist of the NMDA receptor (Fig. 3) nor the AMPA receptors which underlie the fEPSP (Fig 6(WT) and 9(AS).
  • Fig. 3 presents a recording in the CAl region of the hippocampus: EPSCs from a visually identified neuron in hippocampal slices before/after application of CN2097.
  • NMDA-mediated component of the EPSC was isolated in the presence of NBQX (5 ⁇ M) and picrotoxin (50 ⁇ M).
  • APV 50 ⁇ M was added to confirm the NMDA current component, which abolished the EPSC.
  • the cell voltage was clamped at +40 mV and synaptic responses were recorded.
  • Structure 1 composition is administered at 5 mg/Kg orally.
  • the patient exhibits learning of new things that previously she was unable to acquire. Within weeks she is learning words and starts to communicate. As long as the medication is prescribed she is able to continue to learn new things.
  • Chronic treatment with CN 2097 is instituted. The patient maintains the ability to learn new skills and does not exhibit anterograde amnesia.
  • Example 2
  • a new born human infant is identified as having Angelman syndrome as tested by pre- natal genetic screening.
  • Structure 1 composition is administered at 5 mg/Kg subcutaneously.
  • the infant is able to develop normally, and the symptoms of AS do not become manifest.
  • neuronal circuitry is properly developed, preventing the abnormal firing patterns normally seen in AS that result in a high prevalence of epileptic seizures.
  • the infant benefits from acquiring experience induced memories at the critical stages for language and motor development.
  • CN2097 provided protection against NMDA- induced ganglion cell loss in the retina using fluorogold retrograde labeling of surviving ganglion cells viewed 14 days post insult. Data suggest that the regional distribution treated retinas are regionally identical to the distributions in the untreated retina, and are significantly protected as compared with retinas treated with NMDA-alone or those treated with the nonspecific cyclic peptide CN3200/NMDA.
  • Example 3
  • a 50 year old male subject presents with post-stroke inflammation of both retinas.
  • Structure 1 composition is administered at 2 mg/Kg i.v within 3 hours post-stroke.
  • the subject exhibits a subsidence in the inflammation and the retinal cells are protected leading to no loss in visual acuity.
  • NO signaling is examined using guanosine 3',5'-monophosphate (cGMP) formation as a surrogate measure of NO production by Ca2+-activated nNOS56.
  • cGMP guanosine 3',5'-monophosphate
  • CN2097 acts solely on NR2B to promote signaling, neurons will be pre-exposed to the NR2B-specific antagonist Ro 25-6981 or the NR2A-specif ⁇ c antagonist NVP-AAM077.
  • Structure 1 composition is administered at 8 mg/Kg/day orally. Within 6 months, diagnosed AS cognitive defects are significantly reduced and 10 years later with continued medication the subject is normal.
  • CN2097 the human plasma half-life of CN2097 is about 48 minutes, with particular reference to 48.2 minutes.
  • Post i.v. CN2097 uptake into the brain has also been noted with particular reference to the hippocampus, the cerebellum and the periventricular nucleus of the hypothalmus. In addition uptake into the deep cerebellar nuclei, in the sub-cortex and the retina are noted.
  • the pharmacologically active compositions of this invention can be processed in accordance with conventional methods of Galenic pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. Dosages from about lmg to about 10 mg per kilogram are noted with reference to about 4 to about 6 mg/Kg and particularly about 5 mg/Kg. As measured by blood levels a level of about 0.1 to about lO ⁇ M is noted. Particular reference is made to a therapeutic concentration range of about l ⁇ M to about 4 ⁇ M, and more particularly at about 2 ⁇ M.
  • compositions of this invention can be employed in admixture with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, or enteral (e.g., oral or inhalation) use which do not deleteriously react with the active compositions.
  • suitable pharmaceutically acceptable carriers include but are not limited to water andsalt solutions, e.g., saline.
  • the pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., salts for influencing osmotic pressure, buffers and the like which do not deleteriously react with the active compositions. They can also be combined where desired with other active agents, e.g., TPA (Tissue Plasminogen activator).
  • TPA tissue Plasminogen activator
  • dosage forms include instructions for the use of such compositions.
  • injectable, sterile solutions preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including
  • suppositories are convenient unit dosages.
  • Sustained or directed release compositions can be formulated, e.g., liposomes or those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. It is also possible to freeze-dry the new compositions and use the lyophilizates obtained, for example, for the preparation of products for injection.
  • the compositions of this invention are dispensed in unit dosage form comprising about 1 to about 500 mg in a pharmaceutically acceptable carrier per unit dosage.
  • the dosage of the compositions according to this invention generally are 1 to 100 mg/kg/day, preferably 1 to 10 (especially if the general dosage range spans an order of magnitude or more), when administered to patients, e.g., humans to treat (e.g., cardiac insufficiency) analogously to the known agent (hydrochlorothiazide (HydroDIURIL®), and is to 25-50 mg daily TID mg/kg/day when administered to treat (hypertension); (repeat for all activities and indications).
  • treat as an IV bolus then IV infusion similar to Thrombolytic agents such as alteplase (TPA). or antiarrhythmic drugs e,g, atenolol ( IV 50 10 mg) or anti-Parkinson drugs benztropine (Congentin®) IV 1-6 mg daily, or entacapone 200- 1,600 mg.
  • compositions in a specific case will vary according to the specific compositions being utilized, the particular compositions formulated, the mode of application, and the particular situs and organism being treated. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compositions and of a known agent, e.g., by means of an appropriate, conventional pharmacological protocol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention discloses CN2097-like compositions that facilitate the induction of long-term potentiation (LTP). In one embodiment the method comprises inducing long-term potentiation in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound.

Description

Long Term Potentiation with Cyclic-GluR6 Analogs
Field of the Invention
This invention employs a composition (shown below) that facilitates the induction of long-term potentiation (LTP). Without being bound by any particular theory, it is believed that LTP is the cellular manifestation of learning and memory.
The composition (one analog of which is termed CN2097) is a reversible modulator of at least one neuron-specific PDZ domain comprising
Structure 5
Figure imgf000002_0001
R is a molecular transporter with or without a linker amino acid;
Ri is at least about one amino acid covalently bound; and,
R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use. Disruptions in LTP lead to disruptions in memory and has been associated with several neurological disorders, including autism syndromes and neurodegenerative disorders. The application of CN 2097 during the induction of LTP with a stimulus that is normally insufficient, results in the successful induction of LTP. Background of the Invention
There are currently no treatments available that facilitate LTP and there are no clinical trials of such products. LTP failure is implicated in Angelman Syndrome. Without being bound by any particular theory, it is believed that Angelman syndrome (AS) is a neuro-genetic disorder characterized by intellectual and developmental delay, sleep disturbance, seizures, jerky movements especially hand-flapping, frequent laughter or smiling, and usually a happy demeanor. Some in the art believe that AS is a classic example of genetic imprinting in that it is usually caused by deletion or inactivation of genes on the maternally inherited chromosome 15. The related syndrome, Prader-Willi syndrome, is believed caused by a similar loss of paternally- inherited genes.
CN2097 and related compounds are presented in U.S. Provisional Patent Application
Serial No. 61/179,055, entitled "Cyclic-GluR6 Analogs, Methods of Treatment and Use" (Spaller et al.) the teachings of which are incorporated herein by reference in their entirety. CN 2097 is a peptidomimetic drug that selectively targets the PDZ binding domain of the PSD-95, a scaffolding protein involved in the development and regulation of neuronal synapses CN 2097 has demonstrated specificity for the NMDA receptor 2B (NR2B) subunit. The association of PSD-95 with NMDA receptors is an element in the propagation of the synaptic changes of LTP and long-term depression (LTD) that induce learning and memory. PSD-95 is a member of the MAGUK-family of PDZ domain-containing proteins. Its basic structure includes three PDZ domains, an SH3 domain, and a guanylate kinase-like domain (GK).
Angelman syndrome is a result of loss-of-function mutations or deletions in the maternally inherited allele of UBE3A. Mice that are deficient in maternal Ube3a also show genetically reversible deficits in learning and the induction of hippocampal long-term potentiation (LTP)1"3, a form of synaptic plasticity. Angelman syndrome (AS) is caused by disruptions in function due to mutations and/or deletions in the maternally inherited allele of an E3 ubiquitin ligase, UBE3A, a gene that has also been implicated in the broader spectrum of Autism patients. A mouse model for AS carries the maternally inherited Ube3a-null mutation and shows profound impairments in hippocampal synaptic plasticity as seen in Fig. 8. It has been reported that UBE3 A is also required for experience dependent maturation in the visual cortex. In particular, AS mice show deficits in long-term potentiation (LTP) and long-term depression (LTD), which are the cellular substrates of learning and memory. These forms of synaptic plasticity are highly regulated by activity-dependent changes in the ratio of NMDA subunits, specifically NR2A and NR2B subunits. NMDA receptors gate the influx of calcium ions across the post-synaptic membrane. Depending on the characteristics of the calcium influx generated in response to pre-synaptic activity, either LTP or LTD can be induced. This calcium influx activates calcium-dependent enzymes such as CaMKII, which has been strongly implicated in Angelman syndrome, and triggers its autophosphorylation at Thr286. This autophosphorylation is very important as it allows the enzyme to remain active once the calcium levels return to normal. This pathway requires an interplay between the NMDA receptor, CaMKII and a post-synaptic scaffolding protein (PSD-95 in particular), which brings these biochemical elements into proximity. Thr286 autophosphorylation is instrumental in promoting the association of CaMKII with the PSD by directly binding to the NMDA receptor.
Interestingly, there is also a secondary inhibitory autophosphorylation at Thr305/306 that has been suggested to regulate the association of CaMKII to the PSD. Interplay between these states can govern the availability of CaMKII to regulate synaptic plasticity in response to calcium influx during learning and memory activity. The clinical features of AS have been linked to the misregulation of alpha CaMKII function. The role of CaMKII in synaptic plasticity and AS has been investigated at the synapses of the Schaffer-collateral-CAl pyramidal cells in the adult hippocampus.
Noted is the Szeto-Schiller (SS) peptide (Dmt-D-Arg-Phe-Lys-NH2; where Dmt =2',6'- dimethyltyrosine). This represents an approach with targeted intracellular delivery, including to the inner mitochondrial membrane. The structural motif of the SS peptide centers on alternating aromatic residues and basic amino acids (aromatic-cationic peptides). They are small, easy to synthesize, readily soluble in water, and resistant to peptidase degradation. The presence of a D- amino acid in either the first or second position renders them resistant to aminopeptidase activity, and amidation of the C-terminus reduces hydrolysis from the C-terminus. Despite carrying 3+ net charge at physiological pH, these peptides have been reported to readily penetrate cell membranes of a variety of cell types. This is further set forth
in Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HH. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther. 2003;304:425- 432. PubMed DOI: 10.1124/ipet.102.040147
Noted are neurotrophins. Neurotrophins are a family of neurotrophic factors involved in the development, maintenance, and repair of the nervous system. The neurotrophin family consists of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin- 3 (NT-3) and NT-4/5. The neurotrophins are believed to bind to and activate Trk family proteins, the receptor tyrosine kinases (RTK), to exert their effects. NGF binds to TrkA, BDNF and NT- 4/5 bind to TrkB, and NT-3 binds to TrkC. The neurotrophins BDNF and NGF and their high- affinity receptor Trk receptor are reported as widely expressed in neurons throughout the central nervous system. Binding of neurotrophins to Trk receptor is reported to result in
phosphorylation of tyrosine residues in the cytoplasmic domain of the receptor and subsequent recruitment and activation of various signaling adaptor proteins, including She, Gabl, and shp2. Attention is drawn to the following publications the teachings of which are incorporated herein by reference in their entirety as are all references cited herein.
1. Jiang, Y.-h. et al. Mutation of the Angelman Ubiquitin Ligase in Mice Causes Increased
Cytoplasmic p53 and Deficits of Contextual Learning and Long-Term Potentiation.
Neuron 21, 799-811 (1998).
2. Weeber, E.J. et al. Derangements of Hippocampal Calcium/Calmodulin-Dependent
Protein Kinase II in a Mouse Model for Angelman Mental Retardation Syndrome. J.
Neurosci. 23, 2634-2644 (2003).
3. van Woerden, G.M. et al. Rescue of neurological deficits in a mouse model for
Angelman syndrome by reduction of [alpha] CaMKII inhibitory phosphorylation. Nat Neurosci 10, 280-282 (2007).
4. Yi, J.J. & Ehlers, M. D. Emerging Roles for Ubiquitin and Protein Degradation in
Neuronal Function. Pharmacol Rev 59, 14-39 (2007).
5. Yi, J.J. & Ehlers, M.D. Ubiquitin and Protein Turnover in Synapse Function. Neuron 47, 629-632 (2005).
6. Elgersma, Y. et al. Inhibitory Autophosphorylation of CaMKII Controls PSD
Association, Plasticity, and Learning. 36, 493-505 (2002). 7. Elgersma, Y., Sweatt, J.D. & Giese, K.P. Mouse Genetic Approaches to Investigating Calcium/Calmodulin-Dependent Protein Kinase II Function in Plasticity and Cognition. J. Neurosci. 24, 8410-8415 (2004).
8. WaIz NC, B. G. Sensory processing patterns in persons with Angelman syndrome. Am J Occup Ther. 60, 472-9 (2006).
9. Charles, A.W. et al. Angelman syndrome 2005: Updated consensus for diagnostic
criteria. American Journal of Medical Genetics Part A 140A, 413-418 (2006).
10. Oh-Nishi, A., Saji, M., Satoh, S. Z., Ogata, M. & Suzuki, N. Late phase of long-term potentiation induced by co-application of N-methyl-d-aspartic acid and the antagonist of NR2B-containing N-methyl-d-aspartic acid receptors in rat hippocampus. Neuroscience
159, 127-135 (2009).
11. Yashiro, K. et al. Ube3a is required for experience-dependent maturation of the
neocortex. Nat Neurosci advanced online publication(2009).
12. Liu, L. et al. Role of NMDA receptor subtypes in governing the direction of
hippocampal synaptic plasticity. Science 304, 1021-4 (2004).
13. Mallon, A.P., Auberson, Y.P. & Stone, T. W. Selective subunit antagonists suggest an inhibitory relationship between NR2B and NR2A-subunit containing N-methyl-D: - aspartate receptors in hippocampal slices. Exp Brain Res 162, 374-83 (2005).
14. Massey, P.V. et al. Differential Roles of NR2A and NR2B-Containing NMDA
Receptors in Cortical Long-Term Potentiation and Long-Term Depression. J. Neurosci.
24, 7821-7828 (2004).
15. Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 11, 47-60 (1984).
16. Bienenstock, EX., Cooper, L.N. & Munro, P. W. Theory for the development of neuron selectivity: orientation specificity and binocular interaction in visual cortex. J. Neurosci.
2, 32-48 (1982).
17. Giese, K.P., Fedorov, N. B., Filipkowski, R.K. & Silva, A.J. Autophosphorylation at Thr286 of the Alpha} Calcium-Calmodulin Kinase II in LTP and Learning. Science 279, 870-873 (1998).
18. Shen, K. & Meyer, T. Dynamic Control of CaMKII Translocation and Localization in Hippocampal Neurons by NMDA Receptor Stimulation. Science 284, 162-167 (1999). 19. Mallon, A., Auberson, Y. & Stone, T. Selective subunit antagonists suggest an inhibitory relationship between NR2B and NR2A-subunit containing N-methyl-d - aspartate receptors in hippocampal slices. Experimental Brain Research 162, 374-383 (2005).
20. Hardingham, G. E., Fukunaga, Y. & Bading, H. Extrasynaptic NMDARs oppose
synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5, 405-14 (2002).
21. Quinlan, E.M., Olstein, D.H. & Bear, M. F. Bidirectional, experience-dependent
regulation of N-methyl-d-aspartate receptor subunit composition in the rat visual cortex during postnatal development. Proceedings of the National Academy of Sciences of the
United States of America 96, 12876-12880 (1999).
22. Needleman and J. Marshall CamKII phosphorylation of PSD-95 regulates synaptic kainate receptor localization. Submitted.
23. Jeyifous, O.N., LA; Fujisawa, S; Aoki, C; Garner, CC; Marshall, J and Green WN. A role of SAP97 in NMDA receptor sorting and trafficking, submitted.
24. Salinas, G.D., L.A.C. Blair, L.A. Needleman, J.D. Gonzales, Y. Chen, M. Li, J.D.
Singer and J. Marshall. Actinfϊlin is a Cul3 substrate adaptor, linking GluR6 kainate receptor subunits to the ubiquitin-proteasome pathway. J. Biol. Chem. 281(52) :40164- 73.
25. Gao, L., L.A.C. Blair, G.D. Salinas, L.A. Needleman and J. Marshall. (2006). IGF-I- modulation of CaVl.3 calcium channels depends on Ca+2 release from πVsenstitive stores and CaMKII -phosphorylation of the alpha 1 subunit EF hand. J.Neurosci. 26, 6259-68.
26. Gao, L., L.A.C. Blair and J. Marshall. (2006). CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium
channels. Biochem.Biophys.Res.Comm. 354, 1606-10.
27. Wang X, Tang X, Li M, Marshall J, Mao Z. (2005) Regulation of neuroprotective
activity of myocyte-enhancer factor 2 by cAMP -protein kinase A signaling pathway in neuronal survival. J. Biol. Chem 280, 16705-13. 28. Piserchio, A., Spaller, M., Marshall, J., and Mierke, D.F (2004) Targeting specific PDZ domains of PSD-95: Structural basis for enhanced affinity and enzymatic stability of a cyclic peptide Chemistry &Biology 11, 468-473.
29. Ren, Z., Riley, N., Needleman, L., Sanders JM, Swanson GT, Marshall J. (2003) Cell surface expression of GluR5 kainate receptors is regulated by an endoplasmic reticulum retention. J. Biol. Chem. 26;278(52):52700-9.
30. Marshall J, Dolan BM, Garcia EP, Sathe S, Tang X, Mao Z, Blair L.A.C. (2003)
Calcium channel and NMDA receptor activity differentially regulate nuclear C/EBP levels to control neuronal survival. Neuron 39: 625-629.
31. Ren Z, Riley NJ, Garcia EP, Sanders JM, Swanson GT, Marshall J. (2003) A
Trafficking Checkpoint Controls Kainate Receptor Heterodimerization. J. Neuroscience 23, 6608-16.
32. Gong, X., Tang, X., Wiedmann, M., Wang, X., Peng, J., Zheng, D., Blair, L.A.C, Marshall, J., and Mao, Z (2003) Cdk-5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38:33-46.
33. Bowie, D., Garcia, E.P., Marshall, J., Traynelis, S. F. and Lange, G. David (2003) Allosteric Regulation and Spatial Distribution of Kainate Receptors Bound to Ancillary Proteins. J Physiol. 547:373-85.
34. Piserchio, A., Pellegrini, M., Mehta, S., Blackman, S.M., Garcia, E. P., Marshall, J., and Mierke, D.F (2002) Structural Characterization of the Intermolecular Interaction of
SAP90 with the GluR6-subunit of Kainate Receptors J. Biol. Chem. 277: 6967-6973.
35. Mehta, S., Wu, H., Garner, CC, and Marshall, J (2001) Intramolecular interactions regulate SAP97 binding to kainate receptors. J. Biol. Chem. 276: 16092-16099.
36. Savinainen, A., Garcia, E.P., Dorow, D., Marshall, J., and Liu, Y-F (2001) Kainate Receptor Activation Induces Mixed Lineage Kinase-mediated Cellular Signaling
Cascades via Post-synaptic Density Protein 95 J. Biol. Chem. 2001 276: 11382-11386.
37. Fukushima T., Shingai. R., and Marshall, J (2001) Calcium inhibits Willardiine- induced responses in kainate receptor GluR6(Q) and GluR6(Q)/KA-2 Neuroreport 12 163-167.
38. Liu, Y-F., Sudol, M., Marshall, J (2000) Assignment of molecular mechanisms of neuronal death underlying Huntington's disease. J. Biol. Chem. 275, 19035-19040. 39. Bence. K.K., Blair, L.A.C., and J. Marshall. (2000) Potentiation of neuronal L calcium channels by IGF-I requires phosphorylation of the 1 subunit on a specific tyrosine residue. Neuron 27, 121-131.
40. Blair, L.A.C., K.K. Bence and J. Marshall. (2000) GFP in the Study of Neuronal
Signalling Pathways. Current Protocols Neurosci. , vol. 5.15.
41. Blair, L.A.C., K.K. Bence, T. Franke, D. Kaplan and J. Marshall (1999) Akt-dependent potentiation of L channels by IGF-I is required for neuronal survival. J. Neuroscience 19, 1940-51.
42. Garcia, E.P., Mehta, S., Blair, L.A.C., Wells, D.G., Shang, J., Fukushima. T., Fallon, J.R., Garner, CC, and Marshall, J. (1998) SAP90 binds and clusters kainate receptors causing incomplete desensitization. Neuron 21, 727-39.
43. Blair, L.A.C, K.K. Bence and J. Marshall. (1998) The jellyfish green fluorescent
protein: a tool for studying ion channels and second messenger signalling in neurons. Meth.EnzymoL, 302, 213-25.
44. Blair, L.A.C. and Marshall, J. (1997) IGF-I modulates N- and L- calcium channels in a
PI 3-kinase-dependent manner. Neuron 19, 421-429.
45. Moss, G.W.J., Marshall, J., Morabito, M., Howe, J.R. and Moczydlowski, E.G. (1996)
An Evolutionarily Conserved Binding Site for Serine Proteinase Inhibitors in Large
Conductance Calcium- Activated Potassium Channels. Biochemistry 35, 16024-16035. 46. Moss, G.W.J., Marshall, J. and Moczydlowski, E. (1996) A serine Proteinase-like
Domain at the C-terminus of Slowpoke Calcium-activated Potassium channels.
J.Gen.Physiol. 108, 473-484.
47. Marshall, J., Molloy, R., Moss, G., Howe, J.R., Hughes, T.E. (1995) The Jellyfish
Green Fluorescent Protein: A new tool for studying ion channel expression. Neuron 14, 211-215.
48. Kishino, T., Lalande, M., and Wagstaff, J. (1997). UBE3A/E5-AP mutations cause Angelman syndrome. Nat. Genet. 15, 70-73.
49. Albrecht, U., Sutcliffe, J.S., Cattanach, B.M., Beechey, CV., Armstrong, D., Eichele, G., and Beaudet, A.L. (1997). Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat. Genet. 17, 75-78. 50. Jiang, Y., Armstrong, D., Albrecht, U., Atkins, CM., Noebels, JX. , Eichele, G., Sweatt,
D,. and Beaudet, A.L., (1998). Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation.
Neuron 21, 799-811.
51. Minichiello, L., Calella, A.M., Medina D.L., Bonhoeffer, T., Klein, R., and Korte, M.
(2002). Mechanism of TrkB- mediated hippocampal long-term potentiation. Neuron 36,
121-137.
52. Minichiello, L., (2009). TrkB signaling pathways in LTP and learning. Nature 10, 850-
860.
53. Dan, B. (2009). Angelman syndrome: Current understanding and research prospects.
Epilepsia 50:11, 2331-2339.
Brief Description of the Drawings
Fig. 1 is a representation of CN2907.
Fig. 2 shows a sub-threshold LTP induction protocol at the adult Wistar rat Schaffer Collateral-
CAl synapse. It would normally induce no increase in baseline fEPSP responses (lower line).
As shown, this protocol in the presence of CN2097 2μM, results in LTP induction (upper line).
Fig. 3 presents a single, whole cell patch recording of a pharmacologically isolated NMDA excitatory postsynaptic current (EPSC) of a pyramidal neuron in the CAl region of the hippocampus and the lack of effect upon this current by perfusion of CN2097 2μM. APV is a selective NMDA receptor antagonist.
Fig. 4 presents data from a ~2 month WT mouse hippocampal slice , arrow indicates time point at which two High Frequency Stimuli (HFS, 100 pulses in 1 second every 10ms, i.e. 100Hz) separated by 15 seconds were applied, resulting in a significant LTP of 200.03 +- 1.68% averaged over the last ten minutes of the recording (70-80min), n=4, p<0.05.
Fig. 5 presents data from a WT mouse hippocampal slice. An arrow indicates the time point at which one, sub-threshold, High Frequency Stimuli (HFS, 100 pulse in 1 second every 10ms, i.e.
100Hz) was applied, resulting in no significant change in the synaptic strength, 104 +/-0.93%, n=5.
Fig. 6 presents data from a WT mouse adult hippocampal slice. An arrow indicates the time point at which one sub-threshold High Frequency Stimuli (HFS, 100 pulse in 1 second every 10ms, 100Hz) was applied. The white box indicates the treatment with CN2097 2μM. Whilst there is no significant observed effect of CN2097 2μM alone upon baseline responses between 20 and 40minutes, the subsequent HFS at 40minutes results in a significant LTP of 187.2 +/- 1.034% of baseline fESPS slope, n=7.
Fig. 7 presents data from a WT mouse, where CN5135 2μM treatment, combined with HFSl, resulted in no LTP, 103.3% +/-1.085, n=4. CN5135 is a less active analogue of CN2097, with alanine mutations in the 0 and -2 ring positions that contain the posited critical PDZ binding moiety.
Fig. 8 presents data from an AS mouse (Ube3am-/p+) hippocampal slice. Arrow indicates time point at which three trains of High Frequency Stimuli (HFS, 100 pulse in 1 second every 10ms, 100Hz) every 10 seconds, resulting in no significant change in the synaptic strength. At 70-80 minutes the averaged response was 90.33% +/- 1.1, n=3. No other stimulation intensities tested induced LTP in AS mice.
Fig. 9 displays data from AS mouse (Ube3am-/p+) hippocampal slices which were recorded for 0-20 minutes observing a stable baseline. Then CN2097 2μM was superfused from 20-
50minutes. The arrow at 40minutes indicates three trains of High Frequency Stimuli 10 seconds apart . The HFS is 100 pulses in 1 second with an interpulse interval of 10ms, i.e. 100Hz.. This results in a significant increase in the synaptic strength (LTP). In AS mice this stimulation is normally unable to induce LTP (Fig 8.). At 90-100 minutes the averaged response was 159.8 +/- l.l% , n=7.
Fig. 10 displays data from WT mouse szeto-CN2097 (analogue, with Poly Arginine delivery moiety replaced by the 'szeto' sequence), treatment 2μM, combined with HFSl, no LTP was observed , averaged responses at 70-80 minutes were 101.9+/-0.79% of baseline, n=4. Summary of the Invention:
This invention includes inducing long-term potentiation in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound. In some
embodiments the method employs dosage is from about lmg/Kg to about 10 mg/Kg, and particularly from about 4mg/Kg to about 6 mg/Kg, with particular reference to about 5 mg/Kg. In specific embodiments the method of the invention employs dosages which establish a blood and CNS level of about 0.1 to about 10μM, with particular reference to about 2μM to about 4μM.
The method usefully employs CN2907.
Additionally and without being bound by any particular theory, CN 2097 may induce its therapeutic effects by the modulation of other PDZ domains, including, but not limited to, Shank, S-SCAM, Pick, GRIP and MAGI.
In yet another embodiment this invention discloses a method of treating conditions selected from the group consisting of Angelman Syndrome, Alzheimer's Disease, cognitive disorders, learning disorders, or autism spectrum disorders by facilitating the induction of Long- Term Potentiation and Long-term Depression in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound.
Ube3a deficient ("AS") mice were developed previously (Jiang, Y.H. et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21, 799-811 (1998)), were obtained through the Jackson Laboratory. Mice were bred on a 129S7 background. To obtain
heterozygous mice lacking the Ube3a gene maternally (m-/p+), we crossed a heterozygous female mouse (m-/p+) with a wild-type male mouse (m+/p+). Wild type (WT) littermates (m+/p+) were used as controls.
Detailed Description of the Invention.
This invention will be better understood with resort to the following definitions.
A. Cyclic-GluR6 Analogs (CN2907-like compounds) shall mean a composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising
Structure 5
Figure imgf000013_0001
wherein R is a molecular transporter with or without a linker amino acid;
Ri is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine.
B. Long-Term Potentiation (LTP) shall mean a persistent increase in synaptic strength following stimulation of a chemical synapse, including high frequency, chemical, sensory stimulation or as a result of brain activity. "Persistent" in this context shall mean for at least about 30 minutes in -vitro, and with the potential to last indefinitely in-vivo.
The co-application of CN 2097 along with electrical pulses induces LTP in neuronal cells that would normally not be induced, which is a 2-step regimen of drug and pulses. In one embodiment, post-dosing LTP is induced with three, one second, 100Hz pulses of current 10 seconds apart. Without being bound by any particular theory, it is believed that the therapeutic regimen alters (lowers) the experience dependent threshold for the consolidation and acquisition of memory and thus learning. In disorders of memory this drug enhances the encoding of information and skills into long term memory. In addition it is believed to bolster working memory, having a dual effect in both short-term and long-term memory.
In a particular embodiment, this method treats Angelman Syndrome. CN 2097 is a peptidomimetic drug that selectively targets the PDZ binding domain of the PSD-95, a scaffolding protein involved in the development and regulation of neuronal synapses. It is further contemplated as treating neurological conditions characterized by deficits in cognition (primary or co-morbidity) such as schizophrenia, Alzeheimer's disease, Fragile -X syndrome, autism and "life style" drug damage (e.g., methamphetamine, PCP, cocaine etc). The NMDA receptor 2B (NR2B) subunit is involved in learning and memory, including its cellular correlatives, LTP and LTD. CN 2097 was able to lower the threshold for experience-dependent synaptic plasticity. Specifically, an LTP sub-threshold induction protocol that normally does not produce LTP was repeated in the presence of CN 2097 and LTP was elicited. Thus, CN 2097 was able to increase the likelihood that the lower level of stimulation elicited the learning response. Note that synaptic plasticity is where a synaptic signaling event induces a significant and persistent change in synaptic strength, i.e. Increase=LTP,
decrease=LTD. A persistent (greater than 30 minutes post HFS) increase or decrease of at least 10% is generally understood to be significant as compared to baseline (100%) fEPSP slope recordings.
Attention is further drawn to the szeto(SS) peptide analogue of CN 2097 (having szeto instead of the poly-Arg tail); CN5135, and tat-NR2B9c (TAT) whose activity is shown in Fig. 10. Note is made of extrasynaptic receptor populations. By way of non-limiting examples these include GABAA including subunits α5βγ and/or α4βδ, glutamate NR2B and NR2A subunit containing NMDA receptors.
In Angelman Syndrome, changes in the insertion of NR2B and NR2A subunits to the synapse or an alteration in their downstream signaling is thought to decrease the probability of synaptic plasticity induction otherwise produced in normal subjects. Deficits in the induction of synaptic plasticity (LTP and LTD) underlie the learning problems in patients. This in turn increases learning problems. Without being bound by any particular theory it is believed that CN 2097 will lower synaptic plasticity threshold and rescue deficits in LTP, cure the learning deficits and provide an effective treatment for Angelman Syndrome patients.
Using Fmoc-based protocols, a series of peptide ligands were synthesized that
complement the PDZ-binding domain of PSD-95 with the criteria of being membrane permeable, resistant to protease activity and biologically active. The peptide KNYKKTEV, which codes for the CRIPT PDZ-3 binding motif, was cyclized between the valine (V) and threonine (T) residues via beta-alanine linkage and either myristylated (CN2180) or linked to a poly-arginine tail (CN2097; Fig. 1) to enhance its diffusion and uptake capacity by neurons in intact tissues.
Binding specificity of CN2180 was tested against a PDZ-domain array consisting of 96 distinct His-tagged PDZ domains purified and spotted on a gridded nylon membrane. CN2180 showed high specificity to the PDZ1-PDZ2 domains and moderate binding to the PDZ3 domain of PSD- 95, but did not bind to PDZ domains of other MAGUKS or with other PDZ-containing proteins such as MUPPl, S-SCAM, Shank and spinophilin. In electrophysiological and biochemical preliminary studies CN 2097 demonstrates specificity toward the NR2B NMDAR subunit. CN 2097 acts as competitive ligand for this binding site and as such is able to disrupt the normal binding of NR2B receptors to the PSD. Also, it is believed that CN2097 disrupts NR2B downstream signaling by displacing signaling effectors attached directly or indirectly to the NR2B/PSD-95 signaling complex including CaMKII. Excitotoxic studies suggest that CN 2097 is neuroprotective in both the retina and the hippocampus against lethal doses of NMDA.
Without being bound by any particular theory, this effect is believed due to the disruption of apoptotic and necrotic cell signaling pathways that propagate the cell death signal. Neutrophin signaling proteins are believed to link Trk activation to Ras and the downstream activation of mitogen-activated protein kinases (MAPKs) and the
phosphatidylinositol 3-kinase (PI3K)-Akt kinase pathway. Inhibition of p-JNK in particular is a pro-survival effect. JNK is a cell death signaling protein. Additionally, upregulation of CaMKII, an NMDAR-PSD-95 associated protein, is believed to be associated with synaptic plasticity. Biochemical analyses using western blots of in vivo injected retinas, cultured SH-SY5Y neuroblastomas and primary cultured mouse cerebellar granule neurons (CGN) was undertaken. Left and right eyes were given in vivo injections of phosphate buffered saline (PBS), NMDA, NMDA with CN 2097 and NMDA with CN5135, the retinas were then removed and lysed. CGNs were stimulated by a paradigm designed to mimic synaptic stimulation (lOμM glycine, 40μM bicuculline and 4μM picrotoxin in ACSF) and SH-SY5Y cells were activated by nerve growth factor (NGF 50ng/ml). We then probed with antibodies for cell growth and survival pathways and found that 2μM CN2097 yielded a variety effects on the mTOR, S6 and AKT expression pathways including increases in both total protein expression and phosphorylation state (CamKII, ERK, AKT 1/2, p-S6K, p-S6, p- ERK, p-p38) and inhibiting p-JNK. Additionally CN2097 increased the expression CREB, which is also neuroprotective. Also observed were increases in levels of PSD-95. This data are evidence that CN2097 is proviing a neuroprotective effect at the level of the cell death 'master switch'.
tat-NR2B9c (TAT, 2μM), an established NR2B-PDZ peptidomimetic, did not induce detectable pro-survival signaling changes. Western blot analysis of the effects of CN 2097 in cerebellar granule neurons from injected retinas, primary culture (CGN) and a neuroblastoma cell culture line (SH-SY5Y) demonstrated this to be so. CN2097 (2μM) was tested after injection into eyes/retinas (lower left panel) applied to cell cultures for 5-30 minutes
concurrently with either a synaptic stimulation and nerve growth factor (NGF) 50ng/ml .
CN2097 saw increased ERK, AKT 1/2, p-S6K, p-S6, p-ERK, p-p38, p-CREB and PSD-95. Additionally, CN2097 (2μM) inhibited p-JNK. CN2097S (szeto sequence used instead of PoI- Arginine) and CN5135 (2, 10 and 20μM), a structural analogue of CN2097 with disruptive alanine substitutions at the 0 and -2 ring positions (binding domain) were used a negative controls whilst tat-NR2B9c (TAT, 2μM) was used as a positive control. ACPD, an agonist of mGluRl , when CN2097 is added leads to an enhancement of PI3K and AKT signaling.
CN 2097 is effective in synaptic plasticity and is able to lower the threshold for LTP induction, as shown Fig. 2. Fig. 2 shows Sub-threshold LTP induction at the Schaffer Collateral- CAl synapse is rescued by CN 2097. In Fig. 2, using a low intensity 1 second 100Hz (HFS) stimulation train that normally fails to induce LTP (white circles), was added 2μM CN 2097 which induced a significant LTP (black circles) that lasted for over 60minutes. Without being bound by any particular theory, it is believed that CN 2097 acts through its ability to specifically interfere with NR2B activity and expression to change the sliding threshold for synaptic plasticity, altering the ratio of NR2A:NR2B. Similarly, antagonism of NR2B has been reported to lower the threshold for synaptic plasticity, such that LTP can be induced in response to a normally impotent stimulation with NMDA agonist. CN 2097 is believed to mimic this effect without displaying the toxicity and side effects associated with simple receptor antagonists that block basal transmission, since it does not act as an antagonist of the NMDA receptor (Fig. 3) nor the AMPA receptors which underlie the fEPSP (Fig 6(WT) and 9(AS). Fig. 3 presents a recording in the CAl region of the hippocampus: EPSCs from a visually identified neuron in hippocampal slices before/after application of CN2097. Under whole cell configuration, NMDA-mediated component of the EPSC was isolated in the presence of NBQX (5μM) and picrotoxin (50μM). At the end of the experiment, APV (50μM) was added to confirm the NMDA current component, which abolished the EPSC. The cell voltage was clamped at +40 mV and synaptic responses were recorded.
Example 1
Therapeutic Protocol
A 48 year old female presents with Angelman syndrome. Structure 1 composition is administered at 5 mg/Kg orally. The patient exhibits learning of new things that previously she was unable to acquire. Within weeks she is learning words and starts to communicate. As long as the medication is prescribed she is able to continue to learn new things. Chronic treatment with CN 2097 is instituted. The patient maintains the ability to learn new skills and does not exhibit anterograde amnesia. Example 2
Therapeutic Protocol
A new born human infant is identified as having Angelman syndrome as tested by pre- natal genetic screening. Structure 1 composition is administered at 5 mg/Kg subcutaneously. The infant is able to develop normally, and the symptoms of AS do not become manifest. In particular, neuronal circuitry is properly developed, preventing the abnormal firing patterns normally seen in AS that result in a high prevalence of epileptic seizures. Additionally, the infant benefits from acquiring experience induced memories at the critical stages for language and motor development.
Example 2
Therapeutic Retina Protocol The neuroprotective effects of CN2097 post-treatment against NMDA-induced ganglion cell death in the rat retina was observed. Rat eyes were given an intravitreal injection containing 20 nmol of NMDA with 3 nmol CN2097 being co-administered or injected following NMDA insult at 1, 2 or 6hrs. Retinal ganglion cell survival was assessed by counting fluorogold-labeled cells In an defined area (between 2 and 3 mm) from the center of the optic nerve head of each retina and compared with untreated (control) retinas.
This study showed CN2097 attenuation of the signaling of NMDA-induced neuronal cell death in vivo. Matched paired retinas in the presence of CN2097 (indicated in nmol) or absence (zero) displayed a dose dependent attenuation of NMDA-induced poly(ADP-ribosyl)ation- immunoreactivity (PAR-IR) CN2097 blocked NMDA-induced loss of plasma membrane selectivity (LPMS; necrosis) as compared with a time matched NMDA-treated retina. Similarly, CN2097 also blocked NMDA-induced TUNEL-labeling in the retina. Tests included 20 nmol NMDA vs 1.2 nmol CN2097/20 nmol NMDA. CN2097 provided protection against NMDA- induced ganglion cell loss in the retina using fluorogold retrograde labeling of surviving ganglion cells viewed 14 days post insult. Data suggest that the regional distribution treated retinas are regionally identical to the distributions in the untreated retina, and are significantly protected as compared with retinas treated with NMDA-alone or those treated with the nonspecific cyclic peptide CN3200/NMDA. Example 3
Therapeutic Retina Protocol
A 50 year old male subject presents with post-stroke inflammation of both retinas.
Structure 1 composition is administered at 2 mg/Kg i.v within 3 hours post-stroke. The subject exhibits a subsidence in the inflammation and the retinal cells are protected leading to no loss in visual acuity.
NO signaling is examined using guanosine 3',5'-monophosphate (cGMP) formation as a surrogate measure of NO production by Ca2+-activated nNOS56. As p38 is an important downstream effector, and disruption of NR2B/PSD-95 interactions uncouples the NMDAR from p38 activation, we will determine if CN2097 interferes with NMDA stimulation of p38 activation as measured by immunob lotting with an anti-phospho-p38 antibody. Similarly, we have investigated the effects of CN2097 on up-regulating CaMKII, p42/44 MAPK, PI3K- Akt, activation of cAMP response element-binding protein (CREB)-phosphorylation, key mediators of synaptic NMDAR-dependent signaling. To distinguish whether CN2097 acts solely on NR2B to promote signaling, neurons will be pre-exposed to the NR2B-specific antagonist Ro 25-6981 or the NR2A-specifϊc antagonist NVP-AAM077.
Example 4
Chronic Therapeutic Protocol
A 2 year old female presents with AS was identified by clinical presentation. Structure 1 composition is administered at 8 mg/Kg/day orally. Within 6 months, diagnosed AS cognitive defects are significantly reduced and 10 years later with continued medication the subject is normal.
It is noted that the human plasma half-life of CN2097 is about 48 minutes, with particular reference to 48.2 minutes. Post i.v. CN2097 uptake into the brain has also been noted with particular reference to the hippocampus, the cerebellum and the periventricular nucleus of the hypothalmus. In addition uptake into the deep cerebellar nuclei, in the sub-cortex and the retina are noted. The pharmacologically active compositions of this invention can be processed in accordance with conventional methods of Galenic pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. Dosages from about lmg to about 10 mg per kilogram are noted with reference to about 4 to about 6 mg/Kg and particularly about 5 mg/Kg. As measured by blood levels a level of about 0.1 to about lOμM is noted. Particular reference is made to a therapeutic concentration range of about lμM to about 4μM, and more particularly at about 2μM.
The compositions of this invention can be employed in admixture with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, or enteral (e.g., oral or inhalation) use which do not deleteriously react with the active compositions. Suitable pharmaceutically acceptable carriers include but are not limited to water andsalt solutions, e.g., saline. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., salts for influencing osmotic pressure, buffers and the like which do not deleteriously react with the active compositions. They can also be combined where desired with other active agents, e.g., TPA (Tissue Plasminogen activator).
In some embodiments of the present invention, dosage forms include instructions for the use of such compositions.
For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including
suppositories. Ampules are convenient unit dosages.
Sustained or directed release compositions can be formulated, e.g., liposomes or those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. It is also possible to freeze-dry the new compositions and use the lyophilizates obtained, for example, for the preparation of products for injection. Generally, the compositions of this invention are dispensed in unit dosage form comprising about 1 to about 500 mg in a pharmaceutically acceptable carrier per unit dosage.
The dosage of the compositions according to this invention generally are 1 to 100 mg/kg/day, preferably 1 to 10 (especially if the general dosage range spans an order of magnitude or more), when administered to patients, e.g., humans to treat (e.g., cardiac insufficiency) analogously to the known agent (hydrochlorothiazide (HydroDIURIL®), and is to 25-50 mg daily TID mg/kg/day when administered to treat (hypertension); (repeat for all activities and indications). Alternatively, treat as an IV bolus, then IV infusion similar to Thrombolytic agents such as alteplase (TPA). or antiarrhythmic drugs e,g, atenolol ( IV 50 10 mg) or anti-Parkinson drugs benztropine (Congentin®) IV 1-6 mg daily, or entacapone 200- 1,600 mg.
It will be appreciated that the actual preferred amounts of active compositions in a specific case will vary according to the specific compositions being utilized, the particular compositions formulated, the mode of application, and the particular situs and organism being treated. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compositions and of a known agent, e.g., by means of an appropriate, conventional pharmacological protocol.

Claims

We claim:
1. Inducing long-term potentiation in a subject by the method of administering a
therapeutically effective dose of a CN2907-like compound.
2. The method of Claim 1 wherein said dosage is from about lmg/Kg to about 10
mg/Kg.
3. The method of Claim 2 wherein said dosages are from about 4mg/Kg to about 6 mg/Kg.
4. The method of Claim 3 wherein said dosage is about 5 mg/Kg.
5. The method of Claim 1 wherein said dosage establishes a blood level of about 0.1 to about lOμM.
6. The method of Claim 5 wherein said blood level is from about from about 2μM to about 4μM.
7. The method of Claim 1 wherein the CN2907-like compound is CN2907.
8. A method of treating conditions selected from the group consisting of Angelman Syndrome, Alzheimer's disease, cognitive disorders, learning disorders, or autism spectrum disorders by facilitating the induction of Long-Term Potentiation in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound.
PCT/US2010/046891 2009-08-27 2010-08-27 Long term potentiation with cyclic-glur6 analogs Ceased WO2011025906A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/389,047 US8673857B2 (en) 2009-08-27 2010-08-27 Long term potentiation with cyclic-GluR6 analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23734109P 2009-08-27 2009-08-27
US61/237,341 2009-08-27

Publications (1)

Publication Number Publication Date
WO2011025906A1 true WO2011025906A1 (en) 2011-03-03

Family

ID=43628395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/046891 Ceased WO2011025906A1 (en) 2009-08-27 2010-08-27 Long term potentiation with cyclic-glur6 analogs

Country Status (2)

Country Link
US (1) US8673857B2 (en)
WO (1) WO2011025906A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150038671A1 (en) * 2013-05-30 2015-02-05 Keykavous Parang Efficient Synthesis of CN2097 and RC7 and Their Analogs

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135277A2 (en) * 2009-05-18 2010-11-25 Brown University Cyclic-glur6 analogs, methods of treatment and use
US10579350B2 (en) * 2016-02-18 2020-03-03 International Business Machines Corporation Heterogeneous computer system optimization
US20210101935A1 (en) 2019-10-02 2021-04-08 Brown University Cyclic peptidomimetic for the treatment of neurological disorders
WO2022150362A1 (en) * 2021-01-05 2022-07-14 John Marshall Poly-arginine derivatives for enhancing brain-derived growth factor to mitigate neurological disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020129385A1 (en) * 1998-08-17 2002-09-12 Isabelle M. Mansuy Medthods for improving long-term memory storage and retrieval
US20050222093A1 (en) * 2001-03-15 2005-10-06 Rodney Pearlman Methods for restoring cognitive function following systemic stress

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
DE50209178D1 (en) 2002-10-11 2007-02-15 Imvision Gmbh Modular antigen-transporter molecules (MAT molecules) for modulating immune responses, related constructs, methods and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020129385A1 (en) * 1998-08-17 2002-09-12 Isabelle M. Mansuy Medthods for improving long-term memory storage and retrieval
US20050222093A1 (en) * 2001-03-15 2005-10-06 Rodney Pearlman Methods for restoring cognitive function following systemic stress

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PISERCHIO ET AL.: "Targeting Specific PDZ Domains of PSD-95: Structural Basis for Enhanced Affinity and Enzymatic Stability of a Cyclic Peptide.", CHEMISTRY & BIOLOGY, vol. 11, 2004, pages 469 - 473 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150038671A1 (en) * 2013-05-30 2015-02-05 Keykavous Parang Efficient Synthesis of CN2097 and RC7 and Their Analogs

Also Published As

Publication number Publication date
US8673857B2 (en) 2014-03-18
US20120149646A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
US9107868B2 (en) Neuronal pain pathway
Soraci et al. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Levite Glutamate, T cells and multiple sclerosis
Lee et al. Effect of ICV injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats
Horvath et al. Inhibition of microglial P2X4 receptors attenuates morphine tolerance, Iba1, GFAP and μ opioid receptor protein expression while enhancing perivascular microglial ED2
Zadina et al. Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine
Aarts et al. Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors
Harris et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross‐talk between metabotropic glutamate type 5 receptors and N‐methyl‐D‐aspartate receptors
Angelopoulou et al. Pivotal role of Fyn kinase in Parkinson’s disease and levodopa-induced dyskinesia: a novel therapeutic target?
US8673857B2 (en) Long term potentiation with cyclic-GluR6 analogs
Bolton et al. Cellular uptake and spread of the cell‐permeable peptide penetratin in adult rat brain
US20120010148A1 (en) Combination therapies using nap
US10059742B2 (en) Peptides and methods and uses thereof for preventing retinal disorders
US20210347821A1 (en) Inhibitors of pick1 and uses thereof
Wei et al. Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats
Liu et al. Neuroprotective effect of pseudoginsenoside-F11 on permanent cerebral ischemia in rats by regulating calpain activity and NR2A submit-mediated AKT-CREB signaling pathways
EP1383497B1 (en) Carbonic anhydrase activators for enhancing learning and memory
US6426401B1 (en) Pharmaceutical composition containing an inhibitor of immunoglobulin-receptor interaction
Cieslik et al. Regulation of glutamatergic activity via bidirectional activation of two select receptors as a novel approach in antipsychotic drug discovery
Yang The differential regulation of subtypes of N-methyl-D-aspartate receptor in CA1 hippocampal neurons by G protein coupled receptors
US20140249090A1 (en) Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
Kafarski OF DRUG DESIGN
CN115362001A (en) Lipid-conjugated peptide inhibitors of PICK1
Roberts The role of glial activation in descending facilitation from the rostroventromedial medulla (RVM) in models of persistent pain
Rea Nitric oxide synthase: Circulatory effects in Bufo marinus and Rana catesbeiana

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812634

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13389047

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10812634

Country of ref document: EP

Kind code of ref document: A1